Kivu Bioscience Kivu Bioscience Kivu Bioscience

Kivu Bioscience

Pioneering next-generation antibody-drug conjugates (ADC's) in oncology

Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology. The company’s linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. With multiple ADC programs in development and a team of industry veterans, Kivu is advancing its two assets to clinical trials and achieve a robust clinical proof of concept. The company is headquartered in Delaware.

Détails de l'investissement

Employés

8

Pays

USA

I am grateful to be working with a top-tier group of investors and drug developers who are inspired by patients, fueled by data to rapidly develop transformative cancer medicines

Mohit Trikha, Ph.D.

President & COO

quote picture Kivu
Partnership Gimv Partnership Gimv Partnership Gimv

Partnership Gimv

The ambition of Kivu Bioscience holds great potential to significantly enhance patient outcomes in the future. We are excited to work alongside co-investors and the management team to join forces and make Kivu a leading ADC company while bringing new therapeutic solutions to the market.

Deal Team

Portret Michaël Vlemmix
Michaël
Vlemmix

Partner

Belgique
Portret Christoph Kocher
Christoph
Kocher

Principal

Allemagne